IL2 and melanoma: Overall, the duration of response in each group was less than anticipated based on prior reports with IL-2 monotherapy from our group and others.21 25 The shorter than anticipated response duration may have been due to prior therapy altering the immune response or the responsiveness of the melanoma to an IL-2-based regimen.